KOMBIGLYZE XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KOMBIGLYZE XR is an oral extended-release tablet combining two antidiabetic agents approved in 2010 for type 2 diabetes management. The product represents a fixed-dose combination approach to improve patient adherence and glycemic control. Mechanism of action involves dual pharmacologic pathways to address hyperglycemia.
$0.019BPart D
LOE ApproachingDeclining
11mo to LOEProduct is in final years pre-LOE with modest Medicare claims volume; commercial team likely focused on defending market share against generic entry and newer competitors.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Korean Post-marketing Surveillance for Kombiglyze XR®
Started Nov 2012
755 enrolled
Diabetes Mellitus, Type 2
Career Relevance
KOMBIGLYZE XR offers limited career growth opportunity given its imminent LOE and negligible linked job posting volume. Working on this product is best suited for professionals seeking to develop cost-containment, market defense, and generic-transition strategies rather than growth-stage brand building.
Brand Manager
Worked on KOMBIGLYZE XR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.